Reassessment of nefazodone.
S G
SG
Bryant
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017374:Paroxetine / Q000008:administration & dosage*; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D020280:Sertraline; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D015057:1-Naphthylamine; D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D014230:Triazoles; C051752:nefazodone